2017 Chemotherapy Immunity 
European Pharmaceutical Review
JANUARY 26, 2023
CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Of those who receive a transplant, about 50 percent will ultimately relapse, stated research from 2017, published in the journal Blood. Could CAR T therapies be manufactured in one day?
European Pharmaceutical Review
DECEMBER 12, 2023
He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 4, 2023
Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2017; 8(43): 75712–26.
pharmaphorum
JULY 2, 2021
Merck’s drug has been approved for this use since 2017, but failed to show a statistically significant improvement over third-line chemotherapy in either of two confirmatory trials – KEYNOTE-061 and KEYNOTE-062. The data means that immunotherapy has now moved earlier in the treatment pathway.
STAT
MARCH 6, 2023
Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.
pharmaphorum
DECEMBER 21, 2020
California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 months in patients treated with chemotherapy. Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. billion (see below). months, compared with 6.7 Johnson and Johnson & Momenta.
Pharmaceutical Technology
AUGUST 1, 2022
AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. AMR is already the third leading cause of death worldwide, causing around 1.27
Expert insights. Personalized for you.
124 
Let's personalize your content